Prevalence of enterotoxigenic Bacteroides fragilis in patients with colorectal cancer: a systematic review and meta-analysis
Frontiers in Cellular and Infection Microbiology · 07.03.2025 · 15
DOI: 10.3389/fcimb.2025.1525609 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 07.03.2025. Verfasst von Shijun Xia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anus & Intestine Surgery, Shenzhen Hospital (Fu Tian) of Guangzhou University of Chinese Medicine, Shenzhen, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Bacteroides fragilis, Bacteroides Infections. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The gut microbiome, specifically enterotoxigenic Bacteroides fragilis (ETBF), has been reported to play a role in colorectal cancer development. We aimed to conduct a systematic review and meta-analysis of published studies to compare the prevalence of ETBF in patients with colorectal cancer and healthy controls as well as in various stages of colorectal cancer.
Methods
PubMed, EMBASE, and The Cochrane Library were systematically searched for studies published until May 2024. We utilized studies either comparing the prevalence of ETBF in patients with colorectal cancer and healthy control or examining its prevalence across different stages of colorectal cancer. The prevalence of ETBF colonization in biological samples from individuals with colorectal cancer compared to that in healthy controls or adjacent normal tissue as well as the association between the prevalence of ETBF and various stages of colorectal cancer were plotted using a random-effect or fixed-effect model.
Results
Fourteen relevant articles were identified. Meta-analyses revealed that patients with colorectal cancer had a higher likelihood of having ETBF than healthy controls (odds ratio [OR]: 2.54, 95% confidence interval [CI]: 1.63–3.98, I 2 = 55%). Additionally, ETBF detection was lower in stage I/II than in stage III/IV colorectal cancer (OR: 0.61, 95% CI: 0.41–0.91, I 2 = 41%).
Discussion
The prevalence of ETBF was consistently higher in the tissue and fecal samples of patients with colorectal cancer than in those of controls. A difference in ETBF prevalence between stage I/II and stage III/IV colorectal cancer was noted, but further analysis revealed that the conclusion is unreliable. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD 42024548325.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anus & Intestine Surgery, Shenzhen Hospital (Fu Tian) of Guangzhou University of Chinese Medicine, Shenzhen, China.
- Department of Anus & Intestine Surgery, Shenzhen Traditional Chinese Medicine Anorectal Hospital (Fu tian), Shenzhen, China.
- State Key Laboratory of Traditional Chinese Medicine Syndrome/Research Group of Standardization of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospi…
Zitieren
APA
Xia, S., Ma, L., Li, H., Li, Y., & Yu, L. (2025). Prevalence of enterotoxigenic Bacteroides fragilis in patients with colorectal cancer: a systematic review and meta-analysis. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1525609
Vancouver
Xia S, Ma L, Li H, Li Y, Yu L. Prevalence of enterotoxigenic Bacteroides fragilis in patients with colorectal cancer: a systematic review and meta-analysis. Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1525609
BibTeX
@article{Xia2025,
author = {Xia, Shijun and Ma, Lijuan and Li, Hui and Li, Yue and Yu, Linchong},
title = {Prevalence of enterotoxigenic Bacteroides fragilis in patients with colorectal cancer: a systematic review and meta-analysis},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
volume = {15},
doi = {10.3389/fcimb.2025.1525609}
}
EUVIMED